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Background: Pharmacokinetic and pharmacody-
namic proﬁles of exogenous insulin may be affected
by intrinsic factors, such as age, ethnicity/race, and
hepatic and renal function. Insulin degludec (IDeg) is a
basal insulin with an ultralong duration of action and
a ﬂat and stable glucose-lowering effect proﬁle.
Objective: The purpose of this study was to inves-
tigate whether the pharmacokinetic and pharmacody-
namic responses to IDeg at steady state vary according
to patient race/ethnicity.
Methods: This randomized, single-center, double-
blind, 2-period crossover trial investigated responses
to IDeg in 59 patients with type 2 diabetes mellitus
from 3 groups: African American, Hispanic/Latino,
and white. Patients were allocated randomly to a
sequence of 2 treatment periods, separated by a 7-
to 21-day washout period, with once-daily IDeg or
insulin detemir dosing for 6 days at a predeﬁned ﬁxed
dose level (0.6 U/kg). Differences in pharmacokinetic
and pharmacodynamic variables among groups were
analyzed using an ANOVA with treatment period, an
interaction between race/ethnicity, and treatment as
ﬁxed factors, subject as a random effect, and residual
variance, depending on treatment.
Results: Total exposure to IDeg during one dosing
interval at steady state (AUCIDeg,τ,SS) was similar amongAccepted for publication December 28, 2013.
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Open access under CC BY-NC-ND license .the racial/ethnic groups (ratio [95% CI]: African Amer-
ican vs white, 1.10 [0.91–1.31]; African American vs
Hispanic/Latino, 1.13 [0.95–1.34]; and Hispanic/Latino
vs white, 0.97 [0.82–1.16]). The total glucose-lowering
effect of IDeg (AUCGIR,τ,SS) was also similar among the
groups, with no statistically signiﬁcant difference in
pairwise comparisons (1940, 1735, and 2286 mg/kg in
African American, white, and Hispanic/Latino patients,
respectively). Steady state was reached in all groups after
2 to 3 days of dosing. In all groups, both exposure and
glucose-lowering effect for IDeg were evenly distributed
between the ﬁrst and second 12 hours of the 24-hour
dosing interval at steady state (mean AUCIDeg,0–12h,SS/
AUCIDeg,τ,SS ¼ 53%–54%; AUCGIR,0-–12h,SS/AUCGIR,τ,SS ¼
47%–52%).
Conclusion: The similar pharmacokinetic and phar-
macodynamic responses to IDeg in 3 racial/ethnic
groups of patients with type 2 diabetes mellitus
suggest that the ﬂat, stable, and ultralong pharmaco-
kinetic and pharmacodynamic proﬁles of IDeg are
preserved irrespective of race/ethnicity. Although insu-
lin doses must be adjusted on an individual basis,
similar pharmacokinetic and pharmacodynamic res-
ponses to IDeg are observed in patients with differing
race/ethnicity. (Clin Ther. 2014;36:507–515) & 2014
The Authors. Published by Elsevier HS Journals, Inc.
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INTRODUCTION
The goal of insulin therapy in patients with type 1
diabetes mellitus (T1DM) and type 2 diabetes mellitus
(T2DM) is to mimic normal endogenous insulin
secretion to maintain control of plasma glucose
levels.1,2 In patients with T1DM or T2DM, inter-
mediate- or long-acting insulins are now widely used
to cover basal insulin needs.3–5
Insulin degludec (IDeg) is a new-generation basal
insulin with an ultralong duration of action. On
subcutaneous injection, IDeg forms long chains of
multihexamers that result in a soluble depot in the
subcutaneous tissue from which IDeg monomers
gradually separate.6,7 IDeg has a distinct, slow, and
continuous absorption into the circulation, leading to
a ﬂat and stable glucose-lowering effect at steady
state.8 This glucose-lowering effect is characterized
by low hour-to-hour and day-to-day variability within
patients.8,9 IDeg has a duration of action that exceeds
42 hours6–8 and a half-life of approximately 25
hours,8 which is approximately twice as long as that
for insulin glargine.8,10
Clinical studies have found that the ultralong and
stable glucose-lowering effect of IDeg can achieve
glycosylated hemoglobin (HbA1c) levels similar to in-
sulin glargine in patients with T1DM and T2DM.11–13
However, pooled data conﬁrm that the improvement in
HbA1c levels with IDeg occurs with fewer hypoglycemic
episodes, particularly nocturnal episodes, than with
insulin glargine.11–14 Furthermore, the pharmacokinetic
and pharmacodynamic proﬁles allow patients to adjust
their injection time when this is more convenient because
of changes in their daily schedules, without compromis-
ing efﬁcacy or tolerability.15
Pharmacokinetic and pharmacodynamic proﬁles of
insulin may be affected by intrinsic factors, such as
age, race/ethnicity, and hepatic or renal function.16
Thus, it is important to determine whether there is a
difference in effect among different patient popul-
ations to provide evidence of consistency of insulin
absorption across different biological factors. The aim
of this study was to investigate whether the pharma-
cokinetic and pharmacodynamic responses to IDeg at
steady state differ in patients of varying race/ethnicity
with T2DM.508MATERIALS AND METHODS
Study Design
This randomized, single-center, double-blind, 2-
period, crossover trial of patients with T2DM inves-
tigated the pharmacokinetic and pharmacodynamic
properties of IDeg in 3 groups of patients based on
their race/ethnicity. These groups were African Amer-
ican, white, or Hispanic/Latino (ClinicalTrials.gov
identiﬁer: NCT01043510).
Each patient was randomly allocated to a sequence
of 2 treatment periods, each with once-daily IDeg or
insulin detemir (IDet) dosing for 6 days at a predeﬁned
ﬁxed-dose level (0.6 U/kg). IDet was included primar-
ily as a control in case differences among the groups
were observed for IDeg. Racial/ethnic differences in
pharmacokinetic and pharmacodynamic parameters
were not seen with IDet, as previously reported17;
IDet data are not included in this report.
Before trial initiation, the protocol was reviewed and
approved by the RCRC Independent Review Board.
The trial was performed in accordance with the
Declaration of Helsinki and its amendments in force
at the initiation of the trial. Patients were informed
verbally and in writing that they could withdraw from
the trial at any time for any reason. Consent was
obtained in writing before any trial-related activities,
and the investigator retained the consent forms.
Study Participants
Eligible male and female participants were aged 18
through 70 years with clinically diagnosed T2DM for
Z12 months. Patients were African American but not
of Hispanic or Latino origin (African American),
white of Hispanic or Latino origin (Hispanic/Latino),
and white not of Hispanic or Latino origin (white). All
patients had a current daily basal insulin requirement
of Z0.2 U/kg and had received this treatment for Z3
months, alone or in combination with r2 oral
antidiabetic agents. All patients had a body mass
index of r40.0 kg/m2, an HbA1c level of r10.0%,
and a fasting C-peptide level of o1.0 nmol/L.
Patients were excluded if they had a history or
presence of cancer, cardiac diseases, proliferative retin-
opathy or maculopathy and/or severe neuropathy, or a
supine blood pressure at screening of Z180 mm Hg
(systolic) and/orZ100 mm Hg (diastolic). Patients were
also excluded if they were receiving current treatment
with systemic corticosteroids, monoamine oxidase inhib-
itors, nonselective β-blockers, growth hormone, herbalVolume 36 Number 4
M. Hompesch et al.products, or nonroutine vitamins. Patients with recurrent
severe hypoglycemia (41 severe hypoglycemic event in
the preceding 12 months) or hypoglycemic unawareness
were excluded, as were women who were pregnant,
intending to become pregnant, or breastfeeding.
Interventions and Pharmacokinetic Sampling
Before entering the IDeg and IDet treatment periods,
patients treated with oral antidiabetic agents under-
went a washout period of at least 7 days for those
receiving sulfonylurea and/or acarbose therapy and at
least 21 days for those receiving metformin therapy.
During this washout period, the patient’s current
insulin regimen was intensiﬁed and/or additional insu-
lin products were added (NPH insulin and/or insulin
aspart), if judged necessary by the investigator, with
the aim of ensuring adequate glycemic control.
IDeg and IDet were provided in 3-mL Penﬁll
cartridges (100 U/mL; Novo Nordisk A/S, Bagsværd,
Denmark). Trial product was administered via subcu-
taneous injection at a dose level of 0.6 U/kg into a lifted
skinfold on the anterior surface of the thigh. Dosing
occurred at approximately 20.00 hours each day.
Both investigator and patients were masked to the
trial treatment. To maintain masking, a person not
otherwise involved in the conduct of the trial prepared
the doses. During treatment periods, blood glucose
levels were controlled by bolus injections of insulin
aspart, which were injected subcutaneously into a lifted
skinfold of the lower abdominal wall. Adjustments of
the bolus doses were supervised by the investigator on
a daily basis and based on daily blood glucose read-
ings. The 2 treatment periods were separated by a
washout period of 7 to 21 days, and patients resumed
their normal insulin treatment during this time.
Blood samples for assessment of serum IDeg con-
centration were taken before each dose (at 15
minutes and 0 hours), at 1- or 2-hour intervals until
24 hours, and then at 30, 36, 48, 72, 96, and 120
hours after the last dose to estimate IDeg concen-
tration in the terminal phase. Serum IDeg concentra-
tions were measured using a speciﬁc ELISA that is
highly speciﬁc for IDeg.
Pharmacodynamic Measurements (Clamp
Procedure)
Immediately after the last dose, a 24-hour euglycemic
glucose clamp was performed using a Biostator con-
trolled glucose infusion system (Life Science Instruments,April 2014Elkhart, Indiana).8 In brief, approximately 5 to 6 hours
before trial product administration, patients received a
variable intravenous infusion of human regular insulin
(Novolins R; Novo Nordisk A/S) or glucose to obtain a
blood glucose target level of 5.0 mmol/L (90 mg/dL).
Blood glucose had to be at the target level no later than
2 hours before trial product administration. From 1
hour before trial product administration, the insulin
infusion rate (if any) was reduced as much as possible
while still keeping the blood glucose concentration at the
clamp target level. During the last 10 minutes, the infu-
sion of insulin was gradually reduced and terminated
immediately before trial product administration. Blood
glucose concentration was maintained at the clamp
blood glucose target level of 5.0 mmol/L (90 mg/dL)
until 24 hours after trial product administration.
The clamp was to be terminated early if the blood
glucose level exceeded 11.1 mmol/L (200 mg/dL)
without any glucose infusion for at least 30 minutes;
however, this did not occur for any participant in this
trial. Patients remained fasting during the entire clamp
procedure, with no oral intake other than water, and
remained in a supine or semisupine position.
Assessments
The aim of the study was to investigate whether the
pharmacokinetic and pharmacodynamic responses of
IDeg at steady state vary among the 3 different groups
of patients based on race/ethnicity. Responses were
based on serum IDeg concentration–time proﬁles and
glucose infusion rate (GIR) proﬁles obtained during a
24-hour dosing interval at steady state. Tolerability
assessments included adverse events (AEs), conﬁrmed
hypoglycemic episodes (either severe as deﬁned by the
American Diabetes Association18 or veriﬁed by a
plasma glucose concentration o3.1 mmol/L [56 mg/
dL]), injection site reactions, ECG, vital signs, physical
examination, and laboratory tolerability parameters.
Data and Statistical Analyses
Total exposure of IDeg at steady state (AUCIDeg,τ,
SS) was calculated as the area under the serum IDeg
concentration–time curve during a 24-hour dosing
interval. Distribution of IDeg exposure was assessed
by comparing the ratios of the AUCIDeg for the ﬁrst
12-hour interval versus the entire 24-hour interval
(AUCIDeg,0–12h,SS/AUCIDeg,τ,SS). To calculate the time
to reach pharmacokinetic steady state, serum IDeg
trough concentrations were measured at the end of509
Clinical Therapeuticseach 24-hour dosing interval. Terminal half-life for
IDeg was estimated from the individual log-
concentration-time proﬁles after the last dose of IDeg
and calculated as log(2)/λz,IDeg,SS.
Total glucose-lowering effect of IDeg at steady state
(AUCGIR,τ,SS; primary end point) was calculated as the
area under the smoothed GIR curve using the linear
trapezoidal technique on interpolated points. The GIR
proﬁles were smoothed by the Loess smoothing
technique using a ﬁxed smoothing parameter of 0.25
and sampling with 5-minute intervals. The distribu-
tion of glucose-lowering effect during a 24-hour dosing
interval at steady state was quantiﬁed by estimating
the ratio of AUCGIR for the ﬁrst 12-hour interval
versus the entire 24-hour interval (AUCGIR,0–12h,SS/
AUCGIR,τ,SS).
The AUCIDeg,τ,SS and AUCGIR,τ,SS were both com-
pared among the racial/ethnic groups using an
ANOVA method with treatment period, and an
interaction between race/ethnicity and treatment, as
ﬁxed factors, subject as a random effect, and residual
variance depending on treatment. AUCIDeg,τ,SS was
log-transformed before analysis, whereas AUCGIR,τ,SS
was analyzed on the original scale because the
prespeciﬁed model on a log scale was not feasible
because of an outlier; sensitivity analyses with this
patient excluded conﬁrmed the results.RESULTS
Study Participants
Of 233 patients screened, 63 (18 African American,
22 Hispanic/Latino, and 23 white) were included inTable I. Baseline characteristics.*
Characteristic African American
Patients, No. 18
Sex (male/female), No. 11/7
Age, y 48.9 (8.4)
BMI, kg/m2 35.3 (3.7)
Duration of diabetes, y 9.3 (3.0)
HbA1c, % 8.3 (1.4)
C-peptide, nmol/L 0.44 (0.24)
BMI ¼ body mass index; HbA1c ¼ glycosylated hemoglobin.
*Data are mean (SD) unless otherwise speciﬁed.
510the trial, randomized, and exposed to the trial prod-
uct. Fifty-seven patients completed the trial (17 Afri-
can American, 22 Hispanic/Latino, and 18 white).
Fifty-nine patients (18 African American, 22 Hispanic/
Latino, and 19 white) completed the IDeg treatment
period and were thus included in the IDeg analyses at
steady state. Baseline characteristics of each race/
ethnicity group are summarized in Table I.
Steady-State Pharmacokinetic Profiles
The mean steady-state IDeg pharmacokinetic pro-
ﬁles were similar for the 3 race/ethnicity groups
(Figure 1). The AUCIDeg,τ,SS was similar for the 3
groups, with mean pairwise ratios between the groups
close to 1 (Table II). The exposure to IDeg was similar
during the ﬁrst and second 12 hours for all 3 groups
because the ratio of AUCIDeg,0–12h,SS/AUCIDeg,τ,SS was
close to 50% in all race/ethnicity groups (African
American, 53%; Hispanic/Latino, 54%; and white,
54%). The terminal half-life for IDeg was within the
same range for the African American (harmonic mean,
28.5 hours), Hispanic/Latino (22.8 hours), and white
(27.1 hours) patients. Pharmacokinetic steady state
for IDeg was reached after 2 to 3 days of dosing in all
3 race/ethnicity groups.
Steady-State Pharmacodynamic Profiles
The GIR proﬁles for IDeg were ﬂat and stable in all
3 race/ethnicity groups (Figure 2). The AUCGIR,τ,SS
was similar among the race/ethnicity groups, with no
statistically signiﬁcant differences in pairwise
comparisons (ie, zero was within the 95% CI of theWhite Hispanic/Latino
23 22
13/10 13/9
55.1 (8.9) 51.5 (8.3)
32.3 (5.6) 30.2 (4.4)
12.1 (6.7) 13.4 (7.5)
8.1 (1.2) 8.4 (1.1)
0.54 (0.27) 0.49 (0.26)
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Figure 1. Mean insulin degludec pharmacokinetic profiles at steady state in African American, white, and
Hispanic/Latino patients with type 2 diabetes mellitus (dose, 0.6 U/kg).
M. Hompesch et al.estimated mean differences among the groups; Table
III). The ratio between the glucose-lowering effect in
the ﬁrst 12 hours and in the whole dosing interval
(AUCGIR,0–12h,SS/AUCGIR,τ,SS) was close to 50% for all
3 race/ethnicity groups (African American, 52%;
Hispanic/Latino, 50%; and white, 47%). This result
indicates that the glucose-lowering effect of IDeg was
evenly distributed between the ﬁrst and second 12
hours of the dosing interval at steady state in all
groups. For all 3 race/ethnicity groups, blood glucose
concentrations were maintained at 5.0 mmol/L (90
mg/dL) throughout the euglycemic clamp. End of
action (deﬁned as the time point when blood glucoseTable II. Total exposure to insulin degludec (IDeg; 0.6 U/
Black, White and Hispanic/Latino patients with
Race/ethnic group Black
AUC IDeg, ,ss (pmol•h/L)
Geometric mean (CV) 131,578 (22)
Group ratio estimates*
Pairwise comparisons (pmol•h/L) [95% CI]
Black vs White 1.10
Black vs 
Hispanic/Latino
Hispanic/Latino vs 
White
*Group ratio estimates are based on least square means.
CV, Coefficient of variation in %
τ
April 2014concentration was consistently 4150 mg/dL [8.3
mmol/L] during the glucose clamp19) did not occur
in any patients; thus, the glucose-lowering effect of
IDeg extended beyond the clamp duration of 24 hours
in all patients in all 3 race/ethnicity groups.
Safety
IDeg was well tolerated, and no unexpected toler-
ability concerns were identiﬁed. There were no ob-
served differences among the 3 race/ethnicity groups
in reported AEs. Sixty-ﬁve treatment-emergent AEs
were reported in 34 patients (55%). All AEs were mild
or moderate. Six of the AEs in 5 patients were judgedkg) at steady state (AUCIDeg,τ,ss) in African American
type 2 diabetes mellitus.
White Hispanic/Latino
120,380 (36) 116,940 (25)
 [0.91, 1.31]
1.13 [0.95, 1.34] 
0.97 [0.82, 1.16]
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Figure 2. Mean glucose infusion rate profiles at steady state in African American, white, and Hispanic/Latino
patients with type 2 diabetes treated with insulin degludec (dose, 0.6 U/kg).
Clinical Therapeuticsto be probably or possibly related to IDeg or insulin
aspart. No severe or serious AEs were reported in this
trial. The most common AEs were headache (16
events in 13 patients) and back pain (5 events in 4
patients). Mild injection-site reactions were reported
in 2 of 4300 injections with IDeg. One reaction in
one patient was classiﬁed as an administration-site
condition, and the other in another patient was
classiﬁed as erythema under skin and subcutaneous
tissue disorders. A total of 44 conﬁrmed treatment-
emergent hypoglycemic episodes were reported in 23Table III. Total glucose-lowering effect of insulin deglud
Black, White and Hispanic/Latino patients wit
Black vs White
Black 
Black vs
*
*
White
512patients treated with IDeg (7 African Americans, 8
Hispanics/Latinos, and 8 whites). No clinically sig-
niﬁcant changes in vital signs, ECG, or laboratory
tolerability parameters were observed during the
study.
DISCUSSION
This clinical trial evaluated the pharmacokinetic
and pharmacodynamic properties of IDeg at
steady state to determine whether speciﬁc dosing
recommendations should be provided to certainec (IDeg; 0.6 U/kg) at steady state (AUCGIR,τ,ss) in
h type 2 diabetes mellitus.
White
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Latino, and white patients with T2DM, the pharma-
cokinetic proﬁles of IDeg at steady state were com-
parable, with total exposure being similar across all 3
race/ethnicity groups. The glucose-lowering effect of
IDeg was ﬂat and stable during a 24-hour dosing
interval, irrespective of race/ethnicity, with total
glucose-lowering effect also similar across all groups.
Furthermore, the glucose-lowering effect extended
beyond 24 hours in all African American, Hispanic/
Latino, and white patients. These results suggest that
the pharmacokinetic and pharmacodynamic proper-
ties of IDeg are preserved among different race/
ethnicity groups.
Reports of differences in the pharmacokinetic and
pharmacodynamic proﬁles of insulins among patients
of differing race/ethnicity are limited.16 There was no
anecdotal evidence of differences among patients of
varying race/ethnicity in the large therapeutic
conﬁrmatory studies of IDeg in patients with T1DM
and T2DM,11,12 although most patients in those trials
were white.11,12 In the present study, the similar results
across racial/ethnic groups are consistent with previous
results for other available insulins. In a study evaluat-
ing the pharmacokinetic and pharmacodynamic prop-
erties of IDet in African American, Hispanic/Latino,
and white patients with T2DM, similar results were
observed among the groups.17 These results are
supported by the ﬁndings in the present study where
no statistically signiﬁcant differences in the
pharmacokinetic and pharmacodynamic proﬁles were
observed between race/ethnicity groups for IDeg and
IDet. Furthermore, no difference in absorption for
insulin aspart was found in patients of differing
race/ethnicity.20 Therefore, it is proposed that for
these insulins, no adjustment of dose is necessary
based on the race/ethnicity of the patient.16 On the
basis of the results in the present study, dosing
recommendations for IDeg should not require speciﬁc
adjustments for race/ethnicity in African American,
Hispanic/Latino, or white patients. The similar time to
reach steady-state IDeg levels with once-daily dosing
across differing patient groups supports these dosing
recommendations.21 However, it is recognized that all
insulins must be adjusted to the clinical response in
each individual given the range of insulin resistance
and clinical responses among individuals.22
One of the strengths of the study design used here is
the acquisition of data at steady state. Because IDegApril 2014reaches clinical steady state within 2 to 3 days in a
once-daily dosing regimen, steady state represents the
longest treatment time for patients in clinical practice
and in this study. Therefore, it is the most clinically
relevant context in which to examine pharmacokinetic
and pharmacodynamic properties of IDeg. Further-
more, this study used a euglycemic glucose clamp,
considered to be the gold standard for assessing the
glucose-lowering effects of insulin products.2
One of the limitations of this study is that the
euglycemic glucose clamp procedure is, by nature,
innately distinct from the clinical environment, mak-
ing it difﬁcult to relate study ﬁndings to clinical
reality. This study was conducted in patients with
T2DM, implying the possibility that the glucose clamp
results might be affected by endogenous insulin
secretion. However, the glucose clamp target was set
relatively low (5.0 mmol/L [90 mg/dL]) to suppress
endogenous insulin secretion, and, as assessed from
the individual C-peptide proﬁles during the glucose
clamp, endogenous insulin secretion was suppressed in
all patients throughout the clamp. Another aspect of
T2DM that could potentially affect the trial results
was the use in some cases of oral antidiabetic agents.
However, patients being treated with oral antidiabetic
agents underwent a washout period before starting on
the trial product. This was to allow estimation of the
pharmacodynamic response of IDeg without interfer-
ence from the effect of concomitant antidiabetic drugs.
In the present study, no obvious differences were
found in the pattern of hypoglycemic episodes among
the 3 groups of varying race/ethnicity. It is possible in
this small group of patients that the rate of hypogly-
cemic events may be artiﬁcially high because of the
study design because patients received a ﬁxed dose
(0.6 U/kg) of insulin that was independent of the
patients’ individual insulin requirement. IDeg should
be titrated in line with individual requirements to
optimize insulin therapy and reduce the risk of
hypoglycemic events.CONCLUSION
IDeg resulted in similar pharmacokinetic and pharma-
codynamic responses in patients with T2DM irrespec-
tive of race/ethnicity. These results conﬁrm that the
ultralong pharmacologic properties of IDeg are pre-
served in the 3 racial/ethnic groups tested. Although
insulin doses must be adjusted on an individual basis,513
Clinical Therapeuticsthe results from this trial imply that no speciﬁc dose
adjustments are required in these populations.ACKNOWLEDGMENTS
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